DDInter481 DDInter1658
Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate cancer has been successful for these patients, the cancer eventually progresses to become resistant to existing therapies. This warrants further treatment. The goal of treatment with darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing quality of life and life expectancy for those with advanced prostate cancer.[A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Darolutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Voriconazole
Darolutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Larotrectinib
Darolutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Darolutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eslicarbazepine
Darolutamide {u} may lead to a major life threatening interaction when taken with {v} Eluxadoline
Darolutamide {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Darolutamide may cause a minor interaction that can limit clinical effects when taken with Voriconazole
Darolutamide may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Darolutamide may lead to a major life threatening interaction when taken with Eluxadoline
Darolutamide may lead to a major life threatening interaction when taken with Berotralstat